SelK promotes glioblastoma cell proliferation by inhibiting beta-TrCP1 mediated ubiquitin-dependent degradation of CDK4. | SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1 mediated ubiquitin-dependent degradation of CDK4. Li J, Zhao L, Wu Z, Huang S, Wang J, Chang Y, Liu L, Jin H, Lu J, Huang C, Xie Q, Huang H, Su Z., Free PMC Article | 09/26/2024 |
DDX18 Facilitates the Tumorigenesis of Lung Adenocarcinoma by Promoting Cell Cycle Progression through the Upregulation of CDK4. | DDX18 Facilitates the Tumorigenesis of Lung Adenocarcinoma by Promoting Cell Cycle Progression through the Upregulation of CDK4. Feng B, Wang X, Qiu D, Sun H, Deng J, Tan Y, Ji K, Xu S, Zhang S, Tang C., Free PMC Article | 05/31/2024 |
Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors. | Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors. Magrath JW, Sampath SS, Flinchum DA, Hartono AB, Goldberg IN, Boehling JR, Savkovic SD, Lee SB., Free PMC Article | 05/7/2024 |
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma. | Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma. Shi Y, Wang Z, Shao Y, Guang Q, Zhang J, Liu B, Wu C, Wang Y, Sui P. | 04/12/2024 |
Deregulation of the p19/CDK4/CDK6 axis in Jak2[V617F] megakaryocytes accelerates the development of myelofibrosis. | Deregulation of the p19/CDK4/CDK6 axis in Jak2(V617F) megakaryocytes accelerates the development of myelofibrosis. Duparc H, Muller D, Gilles L, Chédeville AL, El Khoury M, Guignard R, Debili N, Wittner M, Kauskot A, Pasquier F, Antony-Debré I, Marty C, Vainchenker W, Plo I, Raslova H. | 04/11/2024 |
N6-methyladenosine-induced METTL1 promotes tumor proliferation via CDK4. | N6-methyladenosine-induced METTL1 promotes tumor proliferation via CDK4. Zhang C, Cui Y. | 03/13/2024 |
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. | Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer. Ziegler DV, Parashar K, Fajas L. | 02/1/2024 |
Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation. | Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation. Knight H, Abis G, Kaur M, Green HLH, Krasemann S, Hartmann K, Lynham S, Clark J, Zhao L, Ruppert C, Weiss A, Schermuly RT, Eaton P, Rudyk O., Free PMC Article | 12/22/2023 |
DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. | DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. Fan H, Liu W, Zeng Y, Zhou Y, Gao M, Yang L, Liu H, Shi Y, Li L, Ma J, Ruan J, Cao R, Jin X, Chen J, Cheng G, Yang H., Free PMC Article | 11/30/2023 |
FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy. | FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy. Voigt E, Quelle DE., Free PMC Article | 09/20/2023 |
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma. | METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma. He F, Ren T, Tang X. | 08/25/2023 |
Astragaloside IV promotes keratinocyte proliferation and migration through upregulating lncRNA H19 recruited ILF3 to enhance the stability of CDK4 mRNA. | Astragaloside IV promotes keratinocyte proliferation and migration through upregulating lncRNA H19 recruited ILF3 to enhance the stability of CDK4 mRNA. Wang DD, Zhang LZ, Pang CJ, Ye JZ. | 08/16/2023 |
A Japanese case of familial malignant melanoma with germline CDK4 variant incidentally diagnosed by cancer genome profiling. | A Japanese case of familial malignant melanoma with germline CDK4 variant incidentally diagnosed by cancer genome profiling. Kiyozumi Y, Goto K, Yoshikawa S, Kiyohara Y, Tsushima T, Kado N, Nishimura S, Higashigawa S, Harada R, Kunitomo K, Fukuzaki N, Matsubayashi H. | 08/11/2023 |
CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial. | CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial. Arnaut JRMB, Guimarães IDS, Dos Santos ACE, Rodrigues EM, Machado JRDS, de Melo AC. | 07/3/2023 |
Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4. | Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4. Yang M, Wang X, Ye Z, Liu T, Meng Y, Duan Y, Yuan X, Yue X, Deng W, Liu RY., Free PMC Article | 04/19/2023 |
Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein. | Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein. Thirumal Kumar D, Shaikh N, Bithia R, Karthick V, George Priya Doss C, Magesh R. | 04/19/2023 |
Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment. | Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment. Pandey P, Khan F, Upadhyay TK, Sharangi AB., Free PMC Article | 03/5/2023 |
Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy. | Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy. Giambra M, Di Cristofori A, Conconi D, Marzorati M, Redaelli S, Zambuto M, Rocca A, Roumy L, Carrabba G, Lavitrano M, Roversi G, Giussani C, Bentivegna A., Free PMC Article | 02/17/2023 |
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. | Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Cai Z, Wang J, Li Y, Shi Q, Jin L, Li S, Zhu M, Wang Q, Wong LL, Yang W, Lai H, Gong C, Yao Y, Liu Y, Zhang J, Yao H, Liu Q. | 01/14/2023 |
MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis. | MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis. Li X, Xie S, Xia Q, Yan J, Chen S, Shen J., Free PMC Article | 01/14/2023 |
MDM2 Gene Amplification and Expression of MDM2 and CDK4 are Rare in Ossifying Fibroma of Craniofacial Bones. | MDM2 Gene Amplification and Expression of MDM2 and CDK4 are Rare in Ossifying Fibroma of Craniofacial Bones. Bahceci DH, Jordan RCK, Horvai AE., Free PMC Article | 12/17/2022 |
IKBIP, a novel glioblastoma biomarker, maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4. | IKBIP, a novel glioblastoma biomarker, maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4. Li K, Huang G, Wang Z, Yang R, Zhang W, Ni B, Guan J, Yi G, Li Z, Zhu Q, Peng Q, Yang L, Qi L, Liu Y. | 12/3/2022 |
Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. | Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. Qayoom H, Mehraj U, Sofi S, Aisha S, Almilaibary A, Alkhanani M, Mir MA. | 07/30/2022 |
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. | Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. Martinez-Monleon A, Kryh Öberg H, Gaarder J, Berbegall AP, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros IM, Øra I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros PF, Gordon Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T., Free PMC Article | 07/30/2022 |
The Effects of HER2 on CDK4/6 Activity in Breast Cancer. | The Effects of HER2 on CDK4/6 Activity in Breast Cancer. Sinclair WD, Cui X. | 05/14/2022 |